All In Biotech

Drug Trial Radar · NCT02566252

Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)

A Randomized, Open-label, Crossover Study to Assess the Safety, Tolerability, and Pharmacodynamics of PUL-042 Inhalation Solution in Healthy Subjects and the Effect of Pretreatment With Cromolyn Sodium or Albuterol Sulfate

Last checked: Nov 19, 2026Latest source record: Aug 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jul 2015

Primary completion

Jan 2016

Study completion Mar 2016

Sponsor

Lead sponsor
Pulmotect, Inc.Industry
Sponsor type
Industry
Collaborators
WCCT Global
First posted
Oct 2, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study evaluates the effect of pre-treatment with either cromolyn sodium or albuterol sulfate on the safety and tolerability or PUL-042 Inhalation Solution in healthy subjects.

Conditions

  • Healthy

Interventions

  • PUL-042 Inhalation SolutionDrug

    PUL-042

  • Cromolyn SodiumDrug

    Pre-treatment

  • Albuterol sulfateDrug

    Pre-treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment emergent, treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0)Time frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • WCCT Global

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.